NCT05688189 (BEST/2022) is a NA clinical trial of different starting temperature setting of HFNC in Oxygen Therapy, sponsored by Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico.

Who is sponsoring NCT05688189?

NCT05688189 is sponsored by Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico.

What drugs are being tested in NCT05688189?

Interventions in NCT05688189: different starting temperature setting of HFNC.

What condition does NCT05688189 study?

NCT05688189 studies Oxygen Therapy.

Is NCT05688189 still recruiting?

NCT05688189 is currently completed. Last updated 17 February 2023.

Last reviewed 2023-02-17 · How we verify

NCT05688189: BEST/2022

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Initial Temperature of High Flow Nasal Cannula

Completed NA Last updated 17 February 2023

What this trial tests

NA trial testing different starting temperature setting of HFNC in Oxygen Therapy in 21 participants. Completed in 15 February 2023.

Timeline

18 January 2023

Primary endpoint
6 February 2023

15 February 2023

Quick facts

Lead sponsor	Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	supportive care
Enrollment	21
Start date	18 January 2023
Primary completion	6 February 2023
Estimated completion	15 February 2023
Sites	1 location across Italy

Drugs / interventions tested

different starting temperature setting of HFNC

Conditions studied

Oxygen Therapy — all drugs for Oxygen Therapy →

Sponsor

Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico

Who can join

18 and older, any sex, with Oxygen Therapy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

In the literature there are no indication on which is the best setting of the humidification temperature at the start of treatment with high flow nasal cannula (HFNC) in intensive care unit (ICU). The primary objective of this study is to understand whether there is a difference between the approaches to the humidification temperature for initiating HFNC treatment based on the perceived comfort of ICU patients. We hypothesize that a gradual increase in temperature (31-34-37°C or 34-37°C) could lead to a different comfort as compared to 37°C as initial starting setting. The secondary aim is to assess the patient's dryness and humidity level of the nose.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

The starting temperature of high-flow nasal cannula and perceived comfort in critically ill patients: A pragmatic randomized controlled trial.
Galazzi A, Gambazza S, Binda F, Dossena C, et al · · 2024 · cited 2× · PMID 39293494 · DOI 10.1111/nicc.13159
ESICM LIVES 2023.
· 2023 · cited 2× · PMID 37874422 · DOI 10.1186/s40635-023-00546-y

Verify or expand the search:

Other recruiting trials for Oxygen Therapy

Currently open trials in the same condition.

NCT06816706 — Comparison of Physiological Effects of Two High-Flow Tracheal Oxygen Versus T-Piece During Spontaneous Breathing Trials · NA · recruiting

Other Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico trials

Trials by the same sponsor.

NCT07492433 — Risk Factors, Incidence, and Clinical Impact of Intraluminal Thrombosis Following FET and TEVAR · not yet recruiting
NCT07402174 — EIT- Guided Lung Recruitment in pARDS · NA · not yet recruiting
NCT07234097 — The Influence of Music on perceiVed paIn and leVels of Anxiety whiLe unDergoing transperIneal Prostate Biopsy: the VIVAL · NA · not yet recruiting
NCT07317193 — DEFINING THE GENETIC DRIVERS OF ADULT-ONSET CHOLESTATIC LIVER DISEASE · NA · recruiting
NCT07487961 — Assess Abdominal Aortic Diameter in Females · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05688189 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Last refreshed: 17 February 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05688189.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing